Challenges of Implementation of the National Phenylketonuria Screening Program in Iran: A Qualitative Study

Alireza Heidari1, Mohammad Arab2, Koorosh Etemad3

  • 1Ph.D. Candidate of Health Policy, Department of Management and Health Economic, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Electronic Physician
|December 14, 2016
PubMed

Insights

Implementing Iran's National Phenylketonuria (PKU) Screening Program faces challenges in management, diagnosis, and treatment. Addressing these requires improved awareness, information systems, and stakeholder collaboration for better newborn health outcomes.

Area of Science:

  • Public Health
  • Genetics
  • Pediatrics

Background:

  • Newborn screening (NBS) is crucial for early detection and management of infant conditions.
  • Challenges in implementing NBS programs are common globally.
  • This study focuses on the specific hurdles within Iran's National Phenylketonuria (PKU) Screening Program.

Purpose of the Study:

  • To identify and analyze the challenges encountered in the implementation of Iran's National PKU Screening Program.
  • To provide insights for improving the effectiveness of newborn screening initiatives in the region.

Main Methods:

  • A qualitative study was conducted in 2015.
  • 38 health policymakers, managers, and PKU experts in Iran were purposively selected.
  • Data were collected through semi-structured interviews and analyzed using framework analysis.

Main Results:

  • Implementation challenges were categorized into five main themes: management, diagnosis, treatment, care, and patient family issues.
  • A total of 22 subthemes were identified within these main categories.
  • Findings highlight multifaceted obstacles impacting the PKU screening program's success.

Conclusions:

  • Key recommendations include enhancing managerial stability and stakeholder engagement.
  • Improving parental awareness, utilizing efficient information systems, and ensuring adequate insurance coverage are vital.
  • Legal backing for mandatory screening and addressing family-related problems are necessary for program success.
Abstract

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
52
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
81
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605